July 14 (Reuters) - Keryx Biopharmaceuticals Inc:
* Receives orphan drug designation for krx-0401 (perifosine) for the treatment
of neuroblastoma
* Says krx-0401 is in-licensed by Keryx from AEterna Zentaris in the United
States, Canada and Mexico
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Receives orphan drug designation for krx-0401 (perifosine) for the treatment
of neuroblastoma
* Says krx-0401 is in-licensed by Keryx from AEterna Zentaris in the United
States, Canada and Mexico
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
